![]() |
|
||||||||
dexmedetomidine (Precedex ®)
|
||||||||
|
Alpha2-adrenergic agonist sedative. Dosing (adults): ICU sedation: Initial: Loading infusion of 1 mcg/kg IV over 10 minutes, followed by a maintenance infusion of 0.2-0.7 mcg/kg/hour (individualized and titrated to desired clinical effect); not indicated for infusions lasting >24 hours (Solution must be diluted prior to administration.) Supplied: 100 mcg/ml - 2 ml Injection |
||||||||
etomidate (Amidate ®)
|
||||||||
|
Ultrashort-acting nonbarbiturate hypnotic. Dosing (adults): Anesthesia: Initial: 0.2 to 0.6 mg/kg IV over 30-60 seconds for induction of anesthesia; maintenance: 5-20 mcg/kg/minute. Produces rapid induction of anesthesia with minimal cardiovascular effects.
|
||||||||
ketamine
(Ketalar ®)
|
||||||||
|
Produces a cataleptic-like state in which the patient is
dissociated from the surrounding environment by direct action on the
cortex and limbic system. Releases endogenous catecholamines
(epinephrine, norepinephrine) which maintain blood pressure and heart
rate. Reduces polysynaptic spinal reflexes. Dosing (adults): Anesthesia (sedation, analgesia): IM: 3-8 mg/kg. IV: Range: 1-4.5 mg/kg; usual induction dosage: 1-2 mg/kg. Maintenance: Supplemental doses of 1/3 to 1/2 of initial dose.
|
||||||||
methohexital
(Brevital ®)
|
||||||||
|
Ultra short-acting IV barbiturate anesthetic.
Dosing (adults): Anesthesia: IV: Induction: 50-120 mg to start; 20-40 mg every 4-7 minutes. (doses must be titrated to effect).
|
||||||||
pentobarbital (Nembutal ®)
|
||||||||
|
Short-acting barbiturate with sedative, hypnotic, and
anticonvulsant properties. Dosing (adults): Hypnotic: IM: 150-200 mg. IV: Initial: 100 mg, may repeat every 1-3 minutes up to 200-500 mg total dose. Preoperative sedation: IM: 150-200 mg. Barbiturate coma in head injury patients or status epilepticus: IV: Loading dose: 5-10 mg/kg given slowly over 1-2 hours; monitor blood pressure and respiratory rate; maintenance infusion: initial: 1 mg/kg/hour; may increase to 2-3 mg/kg/hour; maintain burst suppression on EEG. Status epilepticus: IV: Loading dose: 2-15 mg/kg given slowly over 1-2 hours; maintenance infusion: 0.5-3 mg/kg/hour.
Supplied: Injection: 50 mg/ml (20 ml, 50 ml). |
||||||||
propofol
(Diprivan ®)
|
||||||||
|
Dosing (adults): Induction: General anesthesia: ASA I or II, <55 years: 2-2.5 mg/kg IV (~40 mg every 10 seconds until onset of induction). Cardiac anesthesia: 0.5-1.5 mg/kg IV (~20 mg every 10 seconds until onset of induction). Neurosurgical patients: 1-2 mg/kg IV (~20 mg every 10 seconds until onset of induction). Maintenance: ASA I or II, <55 years: IV infusion: Initial: 150-200 mcg/kg/minute for 10-15 minutes; decrease by 30% to 50% during first 30 minutes of maintenance; usual infusion rate: 100-200 mcg/kg/minute (6-12 mg/kg/hour). IV intermittent bolus: 20-50 mg increments as needed. ICU sedation in intubated mechanically-ventilated patients: Avoid rapid bolus injection; individualize dose and titrate to response. Continuous infusion: Initial: 0.3 mg/kg/hour (5 mcg/kg/min); increase by 0.3-0.6 mg/kg/hour (5-10 mcg/kg/min) every 5-10 minutes until desired sedation level is achieved; usual maintenance: 0.3-4.8 mg/kg/hour (5-80 mcg/kg/min) or higher.
|
||||||||
thiopental
(Pentothal ®)
|
||||||||
|
Dosing (adults): Anesthesia: IV: Induction: 3-5 mg/kg. Maintenance: 25-100 mg as needed. Increased intracranial pressure: IV: Children and Adults: 1.5-5 mg/kg/dose; repeat as needed to control intracranial pressure. Seizures: I.V.: 75 to 250 mg/dose, repeat as needed. Renal dosing: crcl <10 ml/minute: Administer 75% of normal dose.
Supplied: Powder for reconstitution: 250 mg, 400 mg, 500 mg, 1 g. |
||||||||
|
|
||||||||
Disclaimer |
||||||||
|
Listed dosages are for - Adult patients ONLY. PLEASE READ THE
DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
GlobalRPH does not directly or indirectly practice medicine or provide
medical services and therefore assumes no liability whatsoever of any
kind for the information and data accessed through the Service or for
any diagnosis or treatment made in reliance thereon. David F. McAuley, Pharm.D., R.Ph. GlobalRPh Inc. |
| Disclaimer Contact Us Privacy Policy Website Search | We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc. |
![]() |
|
